InsiderClue
Stocks · Health care · Pharmaceutical Preparations

GH Research PLC

GHRS Clue Score38
Ireland Fiscal year ends December CIK 0001855129
$21.11 +3.23% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $21.11 +25.21% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 25 Jun 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2019Operating income−0.3Net income−0.3EPS, diluted−0.01Fiscal year 2020Operating income−0.4Net income−0.4EPS, diluted−0.02Fiscal year 2021Operating income−15.1Net income−9.2EPS, diluted−0.21Fiscal year 2022Operating income−30.6Net income−22.5EPS, diluted−0.43Fiscal year 2023Operating income−41.2Net income−35.6EPS, diluted−0.68Fiscal year 2024Operating income−50.3Net income−39.0EPS, diluted−0.75Fiscal year 2025Operating income−60.7Net income−48.3EPS, diluted−0.79
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income −0.3 −0.4 −15.1 −30.6 −41.2 −50.3 −60.7
Net income −0.3 −0.4 −9.2 −22.5 −35.6 −39.0 −48.3
Growth
EPS, diluted −0.01 −0.02 −0.21 −0.43 −0.68 −0.75 −0.79
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2019Operating cash flow−0.3Capital expenditure0.0Free cash flow−0.3Fiscal year 2020Operating cash flow−0.3Capital expenditure0.0Free cash flow−0.3Fiscal year 2021Operating cash flow−15.3Capital expenditure−0.1Free cash flow−15.4Fiscal year 2022Operating cash flow−26.2Capital expenditure−0.1Free cash flow−26.3Fiscal year 2023Operating cash flow−33.3Capital expenditure−0.1Free cash flow−33.4Fiscal year 2024Operating cash flow−42.3Capital expenditure−0.0Free cash flow−42.3Fiscal year 2025Operating cash flow−43.6Capital expenditure−0.1Free cash flow−43.7
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −0.3 −0.3 −15.3 −26.2 −33.3 −42.3 −43.6
Capital expenditure 0.0 0.0 −0.1 −0.1 −0.1 −0.0 −0.1
Free cash flow −0.3 −0.3 −15.4 −26.3 −33.4 −42.3 −43.7
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2019Cash0.5Shareholders’ equity0.4Fiscal year 2020Cash5.9Shareholders’ equity5.7Fiscal year 2021Cash276.8Shareholders’ equity277.2Fiscal year 2022Cash166.0Shareholders’ equity249.8Fiscal year 2023Cash78.4Shareholders’ equity219.0Fiscal year 2024Cash100.8Shareholders’ equity179.0Fiscal year 2025Cash246.3Shareholders’ equity279.7
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 0.5 5.9 276.8 166.0 78.4 100.8 246.3
Shareholders’ equity 0.4 5.7 277.2 249.8 219.0 179.0 279.7

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Balance sheet

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Assets
0.5 5.9 276.8 166.0 78.4 100.8 246.3
n/a 0.0 0.1 0.1 1.1 0.7 0.6
n/a 5.9 279.9 254.4 226.3 188.3 288.2
Growth +4,634.8% −9.1% −11.0% −16.8% +53.1%
Liabilities
n/a 0.2 2.7 4.5 7.3 9.3 8.5
Equity
n/a −0.8 −10.0 −32.5 −67.9 −106.4 −154.4
0.4 5.7 277.2 249.8 219.0 179.0 279.7
Growth +1,316.5% +4,791.9% −9.9% −12.3% −18.3% +56.3%
Per share and net cash
n/a n/a 52.0 52.0 52.0 52.0 62.0
calc n/a n/a 5.33 4.80 4.21 3.44 4.51

Lines marked calc are worked out here from filed figures; point at one for how.